As of May 25
| -3.21 / -0.81%|
The 22 analysts offering 12-month price forecasts for Regeneron Pharmaceuticals have a median target of 480.50, with a high estimate of 668.00 and a low estimate of 325.00. The median estimate represents a +21.80% increase from the last price of 394.49.
The current consensus among 28 polled investment analysts is to Buy stock in Regeneron Pharmaceuticals. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.